European Journal of Clinical Pharmacology

, Volume 26, Issue 5, pp 591–593 | Cite as

Effect of liver failure on the pharmacokinetics of cyclophosphamide

  • F. D. Juma
Originals

Summary

The pharmacokinetics of cyclophosphamide was investigated in 7 patients in severe liver failure. The pharmacokinetic data were compared with those derived from a matched control group of patients with normal liver function. The half-life (t1/2) of cyclophosphamide following intravenous administration in patients with liver failure was 12.5±1.0 h (m±SD), which was significantly longer than in the normal controls in whom it was 7.6±1.4 h (p<0.001). The mean total body clearance (Clt) was significantly smaller in liver failure at 44.8+8.6l·kg−1 than in the controls in whom it was 63.0±7.6l·kg−1 (p<0.01). It is concluded that severe liver disease has a significant effect on the disposition of cyclophosphamide, and that it could lead to accumulation of the drug in the body.

Key words

cyclophosphamide liver failure pharmacokinetics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bagley CM, Bostic F, De Vita T (1973) Clinical Pharmacology of cyclophosphamide. Cancer Res 33: 226–233Google Scholar
  2. Bosch NVD, Vos DD (1980) Some aspects of the gas-liquid chromatographic analysis of cyclophosphamide in plasma. J Chromatogr 183: 49–56Google Scholar
  3. Colvin M (1978) A review of the pharmacology and clinical uses of cyclophosphamide. In: Pinedo (ed) Clinical pharmacology of antineoplastic drugs. Elsevier/North Holland, Biomedical Press, Amsterdam, pp 245–261Google Scholar
  4. Fenselau C, Kan M-NN, Subba Rao, Myles A, Friedman OM, Colvin M (1977) Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans. Cancer Res 37: 258–2543Google Scholar
  5. Gibaldi M, Perrier D (1975) Pharmacokinetics. Marcel Dekker, New YorkGoogle Scholar
  6. Jardine I, Fenselau C, Appler M, Kan MN, Brundrett RB, Colvin M (1978) Quantitation by gas chromatography-chemical ionisation mass spectrometry of cyclophosphamide, phosphoramide mustard and nor-nitrogen mustard in plasma and urine of patients receiving cyclophosphamide therapy. Cancer Res 38: 408–415Google Scholar
  7. Jarman M, Milsted RAV, Smyth JF, Kinas RW, Pankiewicz K, Stec WT (1979) Comparative metabolism of 2-(bis (2-chloroethyl) amino) tetrahydro-2H-1, 3, 2-oxaza-phosphorine 2-oxide (cyclophosphamide) and entimers in humans. Cancer Res 39: 2762–2767Google Scholar
  8. Juma FD, Rogers HJ, Trounce JR, Bradbrook ID (1978) Pharmacokinetics of intravenous cyclophosphamide in man, estimated by gas-liquid chromatography. Cancer Chemother Pharmacol 1: 229–231Google Scholar
  9. Takamizawa A, Matsumoto S, Iwata T (1975) Studies on cyclophosphamide metabolites and their related compounds II. Preparation of an active species of cyclophosphamide and related compounds. J Med Chem 18: 376–383Google Scholar
  10. Wagner T, Heydrich D, Bartels H, Hohorst HJ (1980) The influence of damaged liver parenchyma, renal insufficiency and haemodialysis on the pharmacokinetic of cyclophosphamide and its activated metabolites. Arzneimittelforsch 30: 1588–1592Google Scholar

Copyright information

© Springer-Verlag 1984

Authors and Affiliations

  • F. D. Juma
    • 1
  1. 1.Department of Medicine, College of Health SciencesUniversity of NairobiNairobiKenya

Personalised recommendations